Growth opportunities led by Abbott Laboratories and Alvogen Iceland ehf among others- Technavio

NEW YORK, March 6, 2023 /PRNewswire/ — The osteoarthritis therapeutics market size is estimated to increase by USD 3,962.95 million from 2022 to 2027, with a CAGR of 8.97%, according to a recent market study by Technavio. Abbott Laboratories, Alvogen Iceland ehf, Anika Therapeutics Inc., Avanos Medical Inc., Bayer AG, Bioventus LLC, Boehringer Ingelheim International GmbH, F. Hoffmann La Roche Ltd., Ferring BV, Fidia Farmaceutici Spa, GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Horizon Therapeutics Plc, Johnson and Johnson, Novartis AG, Pacira BioSciences Inc., Pharmed Ltd., Sanofi SA, Viatris Inc., and Zimmer Biomet Holdings Inc.For more insights on the historic (2017 to 2021) and forecast market size (2023 to 2027) – Request a sample report

What`s New?

• Special coverage on the Russia–Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
• Global competitiveness and key competitor positions
• Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial – Buy the report!

Chart & data table on 5-year historic (2017-2021) market size, comparative analysis of segments, and Y-O-Y growth of osteoarthritis therapeutics market

• The market is segmented by product (analgesics and NSAIDs, corticosteriods, viscosupplements, and others) and type (ankle osteoarthritis, hip osteoarthritis, knee osteoarthritis, and others).
• The analgesics and NSAIDs segment will account for a significant share of the market’s growth during the forecast period.
• Chronic joint pain caused by wear and tear is the primary symptom of osteoarthritis. Hence, the treatment approach aims at providing relief for the pain.
• Some of the drugs used to relieve pain in patients with osteoarthritis include analgesics such as acetaminophen and NSAIDs such as Aspirin and CELEBREX
• NSAIDs have anti-inflammatory properties, which is increasing their demand.
• Several manufacturers have developed NSAID-derived drug conjugates and advanced drug delivery systems for NSAIDs. For instance, Pfizer and Eli Lilly have developed a monoclonal antibody (tanezumab) for the management of chronic pain in patients with osteoarthritis.
• Such product launches will contribute to the growth of this segment during the forecast period.

Get insights on the market contribution of various segments including country and
region wise, historic (2017 to 2021) and forecast market size (2023 to 2027) , view a PDF
sample!

Related Reports:

Alzheimer’s Disease Therapeutics Market by Drug Class and Geography – Forecast and Analysis 2022-2026 – size is expected to increase by USD 3.99 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 8.76%, according to the recent market study by Technavio. Furthermore, this report extensively covers market segmentations by drug class (cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and other drug class) and geography (North America, Europe, Asia, and Rest of World (ROW)). View a summary of the report

Women’s Health Therapeutics Market by Type and Geography – Forecast and Analysis 2022-2026 – size is expected to increase by USD 30.35 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 5.74%, according to the recent market study by Technavio. Furthermore, this report extensively covers segmentation by type (fertility, oncology, menopause, infection, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). View a summary of the report

Register for a free trial today and gain instant access to 17,000+ market research
reports. 
Technavio’s SUBSCRIPTION platform

What are the key data covered in this osteoarthritis therapeutics market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the osteoarthritis therapeutics market between 2023 and 2027
• Precise estimation of the size of the osteoarthritis therapeutics market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global osteoarthritis therapeutics market 2017 – 2021
• Exhibit 18: Historic Market Size – Data Table on Global osteoarthritis therapeutics market 2017 – 2021 ($ million)

• 4.2 Product Segment Analysis 2017 – 2021 
• Exhibit 19: Historic Market Size – Product Segment 2017 – 2021 ($ million)

• 4.3 Type Segment Analysis 2017 – 2021 
• Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 – 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)

• 4.5 Country Segment Analysis 2017 – 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis – Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments 
• Exhibit 30: Chart on Product – Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product – Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 Analgesics and NSAIDs – Market size and forecast 2022-2027 
• Exhibit 34: Chart on Analgesics and NSAIDs – Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Analgesics and NSAIDs – Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Analgesics and NSAIDs – Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Analgesics and NSAIDs – Year-over-year growth 2022-2027 (%)

• 6.4 Corticosteriods – Market size and forecast 2022-2027
• Exhibit 38: Chart on Corticosteriods – Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Corticosteriods – Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Corticosteriods – Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Corticosteriods – Year-over-year growth 2022-2027 (%)

• 6.5 Viscosupplements – Market size and forecast 2022-2027
• Exhibit 42: Chart on Viscosupplements – Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Viscosupplements – Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Viscosupplements – Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Viscosupplements – Year-over-year growth 2022-2027 (%)

• 6.6 Others – Market size and forecast 2022-2027
• Exhibit 46: Chart on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others – Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others – Year-over-year growth 2022-2027 (%)

• 6.7 Market opportunity by Product 
• Exhibit 50: Market opportunity by Product ($ million)

7 Market Segmentation by Type

• 7.1 Market segments 
• Exhibit 51: Chart on Type – Market share 2022-2027 (%)
• Exhibit 52: Data Table on Type – Market share 2022-2027 (%)

• 7.2 Comparison by Type 
• Exhibit 53: Chart on Comparison by Type
• Exhibit 54: Data Table on Comparison by Type

• 7.3 Ankle osteoarthritis – Market size and forecast 2022-2027
• Exhibit 55: Chart on Ankle osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Ankle osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Ankle osteoarthritis – Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Ankle osteoarthritis – Year-over-year growth 2022-2027 (%)

• 7.4 Hip osteoarthritis – Market size and forecast 2022-2027
• Exhibit 59: Chart on Hip osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Hip osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Hip osteoarthritis – Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Hip osteoarthritis – Year-over-year growth 2022-2027 (%)

• 7.5 Knee osteoarthritis – Market size and forecast 2022-2027
• Exhibit 63: Chart on Knee osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on Knee osteoarthritis – Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on Knee osteoarthritis – Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Knee osteoarthritis – Year-over-year growth 2022-2027 (%)

• 7.6 Others – Market size and forecast 2022-2027
• Exhibit 67: Chart on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on Others – Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on Others – Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on Others – Year-over-year growth 2022-2027 (%)

• 7.7 Market opportunity by Type 
• Exhibit 71: Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 73: Chart on Market share by geography 2022-2027 (%)
• Exhibit 74: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 75: Chart on Geographic comparison
• Exhibit 76: Data Table on Geographic comparison

• 9.3 North America – Market size and forecast 2022-2027
• Exhibit 77: Chart on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on North America – Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on North America – Year-over-year growth 2022-2027 (%)

• 9.4 Europe – Market size and forecast 2022-2027
• Exhibit 81: Chart on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Europe – Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Europe – Year-over-year growth 2022-2027 (%)

• 9.5 Asia – Market size and forecast 2022-2027
• Exhibit 85: Chart on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Asia – Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Asia – Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
• Exhibit 89: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)

• 9.7 US – Market size and forecast 2022-2027
• Exhibit 93: Chart on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on US – Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on US – Year-over-year growth 2022-2027 (%)

• 9.8 UK – Market size and forecast 2022-2027
• Exhibit 97: Chart on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on UK – Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on UK – Year-over-year growth 2022-2027 (%)

• 9.9 Japan – Market size and forecast 2022-2027
• Exhibit 101: Chart on Japan – Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on Japan – Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on Japan – Year-over-year growth 2022-2027 (%)

• 9.10 Germany – Market size and forecast 2022-2027
• Exhibit 105: Chart on Germany – Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on Germany – Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on Germany – Year-over-year growth 2022-2027 (%)

• 9.11 China – Market size and forecast 2022-2027
• Exhibit 109: Chart on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 110: Data Table on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 111: Chart on China – Year-over-year growth 2022-2027 (%)
• Exhibit 112: Data Table on China – Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 113: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.3 Impact of drivers and challenges 
• Exhibit 114: Impact of drivers and challenges in 2022 and 2027

11 Vendor Landscape

• 11.2 Vendor landscape 
• Exhibit 115: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 116: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 117: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 118: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 119: Matrix on vendor position and classification

• 12.3 Abbott Laboratories 
• Exhibit 120: Abbott Laboratories – Overview
• Exhibit 121: Abbott Laboratories – Business segments
• Exhibit 122: Abbott Laboratories – Key news
• Exhibit 123: Abbott Laboratories – Key offerings
• Exhibit 124: Abbott Laboratories – Segment focus

• 12.4 Anika Therapeutics Inc. 
• Exhibit 125: Anika Therapeutics Inc. – Overview
• Exhibit 126: Anika Therapeutics Inc. – Product / Service
• Exhibit 127: Anika Therapeutics Inc. – Key offerings

• 12.5 Bayer AG 
• Exhibit 128: Bayer AG – Overview
• Exhibit 129: Bayer AG – Business segments
• Exhibit 130: Bayer AG – Key news
• Exhibit 131: Bayer AG – Key offerings
• Exhibit 132: Bayer AG – Segment focus

• 12.6 Bioventus LLC 
• Exhibit 133: Bioventus LLC – Overview
• Exhibit 134: Bioventus LLC – Business segments
• Exhibit 135: Bioventus LLC – Key news
• Exhibit 136: Bioventus LLC – Key offerings
• Exhibit 137: Bioventus LLC – Segment focus

• 12.7 Boehringer Ingelheim International GmbH
• Exhibit 138: Boehringer Ingelheim International GmbH – Overview
• Exhibit 139: Boehringer Ingelheim International GmbH – Business segments
• Exhibit 140: Boehringer Ingelheim International GmbH – Key news
• Exhibit 141: Boehringer Ingelheim International GmbH – Key offerings
• Exhibit 142: Boehringer Ingelheim International GmbH – Segment focus

• 12.8 F. Hoffmann La Roche Ltd. 
• Exhibit 143: F. Hoffmann La Roche Ltd. – Overview
• Exhibit 144: F. Hoffmann La Roche Ltd. – Business segments
• Exhibit 145: F. Hoffmann La Roche Ltd. – Key news
• Exhibit 146: F. Hoffmann La Roche Ltd. – Key offerings
• Exhibit 147: F. Hoffmann La Roche Ltd. – Segment focus

• 12.9 Ferring BV 
• Exhibit 148: Ferring BV – Overview
• Exhibit 149: Ferring BV – Product / Service
• Exhibit 150: Ferring BV – Key offerings

• 12.10 Fidia Farmaceutici Spa 
• Exhibit 151: Fidia Farmaceutici Spa – Overview
• Exhibit 152: Fidia Farmaceutici Spa – Product / Service
• Exhibit 153: Fidia Farmaceutici Spa – Key offerings

• 12.11 GlaxoSmithKline Plc 
• Exhibit 154: GlaxoSmithKline Plc – Overview
• Exhibit 155: GlaxoSmithKline Plc – Business segments
• Exhibit 156: GlaxoSmithKline Plc – Key offerings
• Exhibit 157: GlaxoSmithKline Plc – Segment focus

• 12.12 Horizon Therapeutics Plc 
• Exhibit 158: Horizon Therapeutics Plc – Overview
• Exhibit 159: Horizon Therapeutics Plc – Business segments
• Exhibit 160: Horizon Therapeutics Plc – Key news
• Exhibit 161: Horizon Therapeutics Plc – Key offerings
• Exhibit 162: Horizon Therapeutics Plc – Segment focus

• 12.13 Johnson and Johnson 
• Exhibit 163: Johnson and Johnson – Overview
• Exhibit 164: Johnson and Johnson – Business segments
• Exhibit 165: Johnson and Johnson – Key news
• Exhibit 166: Johnson and Johnson – Key offerings
• Exhibit 167: Johnson and Johnson – Segment focus

• 12.14 Novartis AG 
• Exhibit 168: Novartis AG – Overview
• Exhibit 169: Novartis AG – Business segments
• Exhibit 170: Novartis AG – Key offerings
• Exhibit 171: Novartis AG – Segment focus

• 12.15 Sanofi SA 
• Exhibit 172: Sanofi SA – Overview
• Exhibit 173: Sanofi SA – Business segments
• Exhibit 174: Sanofi SA – Key news
• Exhibit 175: Sanofi SA – Key offerings
• Exhibit 176: Sanofi SA – Segment focus

• 12.16 Viatris Inc. 
• Exhibit 177: Viatris Inc. – Overview
• Exhibit 178: Viatris Inc. – Business segments
• Exhibit 179: Viatris Inc. – Key offerings
• Exhibit 180: Viatris Inc. – Segment focus

• 12.17 Zimmer Biomet Holdings Inc. 
• Exhibit 181: Zimmer Biomet Holdings Inc. – Overview
• Exhibit 182: Zimmer Biomet Holdings Inc. – Business segments
• Exhibit 183: Zimmer Biomet Holdings Inc. – Key news
• Exhibit 184: Zimmer Biomet Holdings Inc. – Key offerings
• Exhibit 185: Zimmer Biomet Holdings Inc. – Segment focus

13 Appendix

• 13.2 Inclusions and exclusions checklist 
• Exhibit 186: Inclusions checklist
• Exhibit 187: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 188: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 189: Research methodology
• Exhibit 190: Validation techniques employed for market sizing
• Exhibit 191: Information sources

• 13.5 List of abbreviations 
• Exhibit 192: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/ 

SOURCE Technavio